Omega-3 Fatty Acids in Sickle Cell Disease

Inclusion Criteria:

Subjects who meet all of the following criteria are eligible for enrollment into the study:

- Participant has signed the informed consent/assent with parent signing informed
consent as age appropriate.

- Established diagnosis of HbSS, HbSC or HbSβo Thalassemia

- History of ≥1 vasoocclusive events (managed at home and/or in hospital) in preceding
12 months.

- Regular compliance with comprehensive care.

- Aged 8 years or greater and less than 26 years.

- At enrollment, subject should be in his/her baseline steady state and not in the midst
of any acute complication due to SCD. Must be at least 2 weeks from infection or
vasoocclusive crisis at time of screening labs

Exclusion Criteria:

- Baseline hemoglobin levels <5.5 gm/dL.

- Inability to swallow capsules

- Poor compliance with previous treatment regimens.

- Hepatic dysfunction

- Renal dysfunction

- PT and/or PTT ≥ 20% outside of normal

- Allergy to fish, shell fish or soy

- Triglyceride levels <80mg/dL.

- Pregnancy.

- Chronic Transfusion Therapy.

- Transfusion within the last 30 days.

- Treatment with any investigational drug or regular fish oil supplementations in last
60 days.

- Currently receiving another investigational agent, or on such an agent with the last
60 days.

- Dosage changes in preceding 3 months if on hydroxyurea

- Diagnosed bleeding disorder or patient on concomitant anti-coagulation.

- Conditional or abnormal result on most recent transcranial doppler or history of
stroke.

- Other active chronic illness that could adversely affect subjects performance

- Children in Care

- Platelet count less than 100,000